Hertfordshire and West Essex Integrated Care System

NHS Hertfordshire and West Essex Integrated Care Board

Evidence Based Intervention

Virulite Cold Sore Machine

July 2022 v1.0

Document Owner:	Dr Rachel Joyce – Medical Director
Document Author(s):	Clinical Policies Group
Version:	V1.0
Approved By:	Commissioning Committee
Date of Approval:	1st July 2022
Date of Review:	1st July 2024

Policy: **Virulite Cold Sore Machine**

The Virulite Cold Sore Machine works by emitting light of a wavelength that its developers claim heals cold sores twice as quickly as using an antiviral cream.

Following several refinements to the device and two clinical trials, Virulite CS has now been accepted as an addition to part IX of the Drug Tariff for England and Wales, (and part 3 of the Scottish Drug Tariff), prescribable on the NHS from 1 January 2008.

Virulite costs £18.50 per machine and they carry a three-year warranty.
The evidence for the effectiveness of these machines either against placebo or topical aciclovir is very limited and no long-term safety data could be found on a search. The evidence relates to crusting or healing rates and not to prevention of recurrence or to use in combination with other treatments.
NHS Clinical Knowledge Summaries states that the benefits of topical antivirals (aciclovir or penciclovir) are small and require treatment to be initiated at the onset of symptoms (erythema or prodromal stage) before vesicles appear. They do not recommend that oral antivirals should be used in immunocompetent individuals for mild-to-moderate episodes given the self-limiting nature of the disease, the limited benefits of oral antivirals, and that treatment needs to be initiated at the onset of prodromal symptoms. They may be of most use in severe cases or in immunocompromised individuals at risk of developing further complications.
In terms of any one specific patient, prescribing the Virulite might be an option if an immunocompetent patient is unable to concord with the usual self-help advice and the administration schedules for more established therapies or is frequently presenting for repeat prescriptions. However, that this product should NOT be prescribed routinely for herpes labialis until such time more robust evidence of benefit is available.

The Human Rights Act has been considered in the formation of this policy statement.

Patients who are not eligible for treatment under this policy may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. Individual cases will be reviewed as per the ICB policy.

Change History:

Version	Date	Reviewer(s)	Revision Description

DOCUMENT CONTROL

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the website.

Do you really need to print this document?
Please consider the environment before you print this document and where copies should be printed double-sided. Please also consider setting the Page Range in the Print properties, when relevant to do so, to avoid printing the policy in its entirety.